| Literature DB >> 30420952 |
Tingting He1,2, Yuan Liu3, Yueyue Jia4, Haiyan Wang5, Xiao Yang1,2, Gang Lu6, Hongbin Liu1,2,6, Yuhua Shi1,2.
Abstract
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in reproductive-aged women, affecting 6-8% of women and characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. Accumulating evidence demonstrates that different microRNAs (miRNAs) expressions may contribute to the pathogenesis of PCOS. Therefore, the goal of this study is to compare the expression levels of miR-141 and miR-200c in granulosa cells isolated from PCOS patients and also evaluate their predictive values for pregnancy complications. First, RNA extraction, reverse transcription, and reverse transcription-polymerase chain reaction (RT-PCR) were performed to assess the expression levels of miR-141 and miR-200c in granulosa cells isolated from 62 PCOS patients and 61 controls. Second, according to each mean of miR-141 and miR-200c measured values in all patients, PCOS, and controls were divided into low-expression group and high-expression group to better evaluate their predictive values for pregnancy complications. Significantly elevated expressions of miR-141 and miR-200c were observed in PCOS patients compared with the controls (p < 0.001 and p = 0.002, respectively). Furthermore, PCOS patients had a significantly increased incidence of pregnancy complications in low-expression groups of miR-141 and miR-200c (p = 0.007 and p = 0.002, respectively). Our findings demonstrated that the expressions of both miR-141 and miR-200c were significantly increased in PCOS patients, which might contribute to the pathogenesis of PCOS. PCOS patients had an increased risk of pregnancy complications in low-expression groups of both miR-141 and miR-200c.Entities:
Keywords: granulosa cells; miR-141; miR-200c; polycystic ovary syndrome; pregnancy complications
Year: 2018 PMID: 30420952 PMCID: PMC6215824 DOI: 10.3389/fmed.2018.00299
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Clinical and endocrine parameters in PCOS patients and controls.
| Age (years) | 28.27 ± 3.10 | 28.71 ± 2.46 | 0.362 |
| BMI (kg/m2) | 24.40 ± 3.34 | 21.77 ± 2.37 | |
| FPG(mmol/L) | 5.36 ± 0.47 | 5.19 ± 0.43 | 0.032 |
| FINS(mIU/L) | 14.50 ± 7.18 | 7.86 ± 1.94 | |
| HOMA-IR | 3.67 ± 2.07 | 1.80 ± 0.47 | |
| LH (IU/L) | 8.17 ± 3.84 | 4.90 ± 1.42 | |
| FSH (U/L) | 5.90 ± 1.13 | 6.52 ± 1.04 | 0.001 |
| T(ng/dL) | 36.75 ± 14.59 | 22.75 ± 7.48 | |
| AMH (ng/ml) | 9.40 ± 4.36 | 4.00 ± 1.83 | |
| HDL (mmol/l) | 1.28 ± 0.22 | 1.41 ± 0.20 | |
| LDL (mmol/l) | 3.07 ± 0.37 | 2.79 ± 0.59 | |
| TG (mmol/l) | 1.11 ± 0.45 | 0.79 ± 0.25 | |
| TC (mmol/l) | 4.51 ± 0.52 | 4.30 ± 0.66 | 0.041 |
| AFC (mmol/l) | 26.05 ± 7.98 | 12.91 ± 3.56 |
BMI, body mass index; FPG, fasting plasma glucose; FINS, fasting insulin; HOMA-IR, homeostasis model assessment of insulin resistance; FSH, follicle stimulating hormone; LH, luteotropic hormone; T, testosterone; AMH, anti-Mullerian hormone; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol.
Figure 1The expression of miR-141 and miR-200c in Polycystic Ovary Syndrome (PCOS) and control groups. Results are showed as the mean of (miRNAs of interest/U6) ± SD. (A) Expression of miR-141. (B) Expression of miR-200c. ***p < 0.001, **p = 0.002. PCOS women, n = 62; control women, n = 61. The groups were compared by Student t-test to determine statistical significance, A p-value < 0.05 was considered statistically significant.
Comparison of pregnancy complications with different levels of miR-141.
| miR-141 low-expression group | PCOS ( | 8 | 0.007 |
| Controls ( | 3 | ||
| miR-141 high-expression group | PCOS ( | 4 | 0.611 |
| Controls ( | 2 | ||
Comparison of pregnancy complications with different levels of miR-200c.
| miR-200c low-expression group | PCOS ( | 9 | 0.002 |
| Controls ( | 2 | ||
| miR-200c high-expression group | PCOS ( | 5 | 1 |
| Controls ( | 1 | ||